The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement

Célia Beatriz Gianotti Antoneli, Karina B. Ribeiro, Carlos Rodriguez-Galindo, Fernando A. Soares, Victor A. Arias, Paulo E.R.S. Novaes, Martha M. Chojniak, Marcio Malogolowkin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

This study aimed to determine the impact of the addition of ifosfamide/etoposide to a regimen containing cisplatin/teniposide on the survival of patients with retinoblastoma with orbital involvement. Thirty patients were treated at the A. C. Camargo Hospital, Brazil, from 1986 to 2002. From 1986 to April 1992 (period I, n=12), treatment consisted of 3 cycles of induction chemotherapy with cisplatin and teniposide, followed by maintenance with same drugs alternating with cyclophosphamide, vincristine, and doxorubicin every 21 days for 60 weeks. Since April 1992 (period II, n=18), the treatment consisted of 3 cycles of ifosfamide and etoposide followed by maintenance with same drugs, alternating with cisplatin and teniposide every 21 days for 36 weeks. In both periods, children were submitted to exenteration with eyelid preservation and orbital radiation therapy with 45 cGy, and also received intrathecal therapy with methotrexate plus dexamethasone and cytarabine. Kaplan-Meier method was used for survival analysis. The median age was 31 months. Most patients (86.7%) presented unilateral tumors. The 3-year overall survival was 34.4% and 72.2%, respectively, for patients treated during periods I and II (P=0.061). The addition of ifosfamide/etoposide to chemotherapy with cisplatin/teniposide improves survival in these patients, but further studies are still necessary.

Original languageEnglish (US)
Pages (from-to)700-704
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume29
Issue number10
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Teniposide
Ifosfamide
Retinoblastoma
Etoposide
Cisplatin
Survival
Maintenance
Induction Chemotherapy
Cytarabine
Vincristine
Eyelids
Survival Analysis
Methotrexate
Pharmaceutical Preparations
Doxorubicin
Cyclophosphamide
Dexamethasone
Brazil
Radiotherapy
Therapeutics

Keywords

  • Chemotherapy
  • Extraocular disease
  • Orbital involvement
  • Retinoblastoma
  • Survival

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. / Antoneli, Célia Beatriz Gianotti; Ribeiro, Karina B.; Rodriguez-Galindo, Carlos; Soares, Fernando A.; Arias, Victor A.; Novaes, Paulo E.R.S.; Chojniak, Martha M.; Malogolowkin, Marcio.

In: Journal of Pediatric Hematology/Oncology, Vol. 29, No. 10, 01.10.2007, p. 700-704.

Research output: Contribution to journalArticle

Antoneli, Célia Beatriz Gianotti ; Ribeiro, Karina B. ; Rodriguez-Galindo, Carlos ; Soares, Fernando A. ; Arias, Victor A. ; Novaes, Paulo E.R.S. ; Chojniak, Martha M. ; Malogolowkin, Marcio. / The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. In: Journal of Pediatric Hematology/Oncology. 2007 ; Vol. 29, No. 10. pp. 700-704.
@article{18a17b7e13724951ad50798ca01e83b7,
title = "The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement",
abstract = "This study aimed to determine the impact of the addition of ifosfamide/etoposide to a regimen containing cisplatin/teniposide on the survival of patients with retinoblastoma with orbital involvement. Thirty patients were treated at the A. C. Camargo Hospital, Brazil, from 1986 to 2002. From 1986 to April 1992 (period I, n=12), treatment consisted of 3 cycles of induction chemotherapy with cisplatin and teniposide, followed by maintenance with same drugs alternating with cyclophosphamide, vincristine, and doxorubicin every 21 days for 60 weeks. Since April 1992 (period II, n=18), the treatment consisted of 3 cycles of ifosfamide and etoposide followed by maintenance with same drugs, alternating with cisplatin and teniposide every 21 days for 36 weeks. In both periods, children were submitted to exenteration with eyelid preservation and orbital radiation therapy with 45 cGy, and also received intrathecal therapy with methotrexate plus dexamethasone and cytarabine. Kaplan-Meier method was used for survival analysis. The median age was 31 months. Most patients (86.7{\%}) presented unilateral tumors. The 3-year overall survival was 34.4{\%} and 72.2{\%}, respectively, for patients treated during periods I and II (P=0.061). The addition of ifosfamide/etoposide to chemotherapy with cisplatin/teniposide improves survival in these patients, but further studies are still necessary.",
keywords = "Chemotherapy, Extraocular disease, Orbital involvement, Retinoblastoma, Survival",
author = "Antoneli, {C{\'e}lia Beatriz Gianotti} and Ribeiro, {Karina B.} and Carlos Rodriguez-Galindo and Soares, {Fernando A.} and Arias, {Victor A.} and Novaes, {Paulo E.R.S.} and Chojniak, {Martha M.} and Marcio Malogolowkin",
year = "2007",
month = "10",
day = "1",
doi = "10.1097/MPH.0b013e31814fb7ea",
language = "English (US)",
volume = "29",
pages = "700--704",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement

AU - Antoneli, Célia Beatriz Gianotti

AU - Ribeiro, Karina B.

AU - Rodriguez-Galindo, Carlos

AU - Soares, Fernando A.

AU - Arias, Victor A.

AU - Novaes, Paulo E.R.S.

AU - Chojniak, Martha M.

AU - Malogolowkin, Marcio

PY - 2007/10/1

Y1 - 2007/10/1

N2 - This study aimed to determine the impact of the addition of ifosfamide/etoposide to a regimen containing cisplatin/teniposide on the survival of patients with retinoblastoma with orbital involvement. Thirty patients were treated at the A. C. Camargo Hospital, Brazil, from 1986 to 2002. From 1986 to April 1992 (period I, n=12), treatment consisted of 3 cycles of induction chemotherapy with cisplatin and teniposide, followed by maintenance with same drugs alternating with cyclophosphamide, vincristine, and doxorubicin every 21 days for 60 weeks. Since April 1992 (period II, n=18), the treatment consisted of 3 cycles of ifosfamide and etoposide followed by maintenance with same drugs, alternating with cisplatin and teniposide every 21 days for 36 weeks. In both periods, children were submitted to exenteration with eyelid preservation and orbital radiation therapy with 45 cGy, and also received intrathecal therapy with methotrexate plus dexamethasone and cytarabine. Kaplan-Meier method was used for survival analysis. The median age was 31 months. Most patients (86.7%) presented unilateral tumors. The 3-year overall survival was 34.4% and 72.2%, respectively, for patients treated during periods I and II (P=0.061). The addition of ifosfamide/etoposide to chemotherapy with cisplatin/teniposide improves survival in these patients, but further studies are still necessary.

AB - This study aimed to determine the impact of the addition of ifosfamide/etoposide to a regimen containing cisplatin/teniposide on the survival of patients with retinoblastoma with orbital involvement. Thirty patients were treated at the A. C. Camargo Hospital, Brazil, from 1986 to 2002. From 1986 to April 1992 (period I, n=12), treatment consisted of 3 cycles of induction chemotherapy with cisplatin and teniposide, followed by maintenance with same drugs alternating with cyclophosphamide, vincristine, and doxorubicin every 21 days for 60 weeks. Since April 1992 (period II, n=18), the treatment consisted of 3 cycles of ifosfamide and etoposide followed by maintenance with same drugs, alternating with cisplatin and teniposide every 21 days for 36 weeks. In both periods, children were submitted to exenteration with eyelid preservation and orbital radiation therapy with 45 cGy, and also received intrathecal therapy with methotrexate plus dexamethasone and cytarabine. Kaplan-Meier method was used for survival analysis. The median age was 31 months. Most patients (86.7%) presented unilateral tumors. The 3-year overall survival was 34.4% and 72.2%, respectively, for patients treated during periods I and II (P=0.061). The addition of ifosfamide/etoposide to chemotherapy with cisplatin/teniposide improves survival in these patients, but further studies are still necessary.

KW - Chemotherapy

KW - Extraocular disease

KW - Orbital involvement

KW - Retinoblastoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=35148814440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148814440&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e31814fb7ea

DO - 10.1097/MPH.0b013e31814fb7ea

M3 - Article

C2 - 17921851

AN - SCOPUS:35148814440

VL - 29

SP - 700

EP - 704

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 10

ER -